(English) Cross-border pharma deal calls on multiple LatAm firms

14 . novembro . 2019 |

Desculpe-nos, mas este texto está apenas disponível em Inglês Americano. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Canadian publicly owned specialty pharmaceuticals company Knight Therapeutics has hired Davies Ward Phillips & Vineberg in Montréal, Pinheiro Neto Advogados in São Paulo, Ferrere (Uruguay), Brigard Urrutia in Bogotá and Beccar Varela in Buenos Aires to buy a majority stake in Uruguayan biopharmaceutical group Biotoscana, in a deal valued at 1.1 billion Brazilian reais (US$273 million).

Montevideo-headquartered Biotoscana hired Lobo de Rizzo Advogados in São Paulo and Posadas, Posadas & Vecino in Montevideo. The company is listed on the Brazilian stock exchange.

Biotoscana’s majority shareholders, Essex Woodlands and Advent International, were the sellers in the deal and relied on in-house counsel and Estudio Garrido Abogados in Buenos Aires. The transaction was signed on 18 October.

It is thought that Arendt & Medernach in Luxembourg City also advised Knight, but the firm did not confirm its participation prior to publishing. Bonn Steichen & Partners in Luxembourg City is also thought to be involved as representatives of Biotoscana, but neither confirmed their role.

Knight obtained a 51% majority stake valued at 595 million reais (US$149 million) from Advent International and Essex Woodlands. It will make a mandatory follow-on tender offer worth 568 million reais (US$142 million) to buy the remaining 49% from minority shareholders.

If shareholders accept the tender offer, the deal will reach a total of 1.1 billion reais (US$273 million), with the combined enterprise valued at a total of 1.3 billion reais (US$323 million).

Biotoscana has operations across 10 different countries within the region, including Brazil, Mexico, Argentina and Chile. The company specialises in providing innovative biopharmaceutical services.

Counsel to Knight Therapeutics

Davies Ward Phillips & Vineberg LLP

Partners Hillel Rosen and Brian Kujavsky and associate Shayna Goldman in Montréal

Pinheiro Neto Advogados

Partner Guilherme Sampaio Monteiro and associates Milena Casado de Oliveira and Taisa Sani in São Paulo

Ferrere (Uruguay)

Partner Martin Cerruti and associates Cristina Vignone, Alejandro Alterwain, Manuel Graña, Carolina Piacenza, Bruno Bertolotti, María Maiorano, Diego Durán, Alberto Baroffio, Alejandra Añon, Martín Pesce, Cecilia Alberti, Joaquín Garino in Montevideo

Beccar Varela

Partners María Shakespear, Roberto Crouzel and Horacio E. Beccar Varela, and associates Luciana Liefeldt, Ana Andres, Florencia Cariella, Tomas Peña, Angeles Murgier, Elias Colabelli and Agustín Waisman in Buenos Aires

Brigard Urrutia

Partner Carlos Urrutia and associates Tomás Holguín and Sergio Andrés Velandia Cetina in Bogotá

Counsel to Grupo Biotoscana

In-house counsel – María Eugenia Cabezas

Lobo de Rizzo Advogados

Partners Rodrigo Millar de Castro Guerra and Paula Magalhães, and associates Julia Visconti, Gabriel Arruda Chueke, Jéssica Pfeifer Dalla Picola in São Paulo

Posadas, Posadas & Vecino

Partners Diego Gamarra, Fernando de Posadas and Diego Cuenca and associate Cecilia Demarco in Montevideo

Counsel to Advent International and Essex Woodlands

Estudio Garrido Abogados

Partners Lucas Granillo Ocampo and Raul Granillo Ocampo, and associates Gisela Marina Montensanto a Regina Gaggiotti in Buenos Aires

This article was updated on 13/11/19 to include Brigard Urrutia’s advice to Knight Therapeutics.

 

Source: Latin Lawyer


ver todas as publicacoes